Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
O'Hear C, Inaba H, Pounds S, Shi L, Dahl G, Bowman WP, Taub JW, Pui CH, Ribeiro RC, Coustan-Smith E, Campana D, Rubnitz JE.
O'Hear C, et al. Among authors: inaba h.
Cancer. 2013 Nov 15;119(22):4036-43. doi: 10.1002/cncr.28334. Epub 2013 Sep 4.
Cancer. 2013.
PMID: 24006085
Free PMC article.
Clinical Trial.